BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), an advanced digital signal processing technology
company delivering unprecedented accuracy and precision to
intracardiac signal visualization with its proprietary PURE EP™
System, today announced the appointment of Lorraine Spurge,
entrepreneur and financier, to its Advisory Board.
As founder and CEO of Maple Stone Capital Advisors, Ms. Spurge
began her 40-year financial career with Drexel Burnham Lambert and
became one of the most successful women on Wall Street. She helped
raise more than $200 billion of debt and equity capital for growth
companies. The capital she helped raise was crucial to hundreds of
companies, including MCI Communications, McCaw Cellular, Warner
Communications, Healthtrust, Charter Medical, Movado, and MGM
Resorts and Studios. After Drexel, she became an entrepreneur and
helped build companies like International Capital Access, Spurge
Ink!, MetWest Financial, and Guggenheim Partners.
Ms. Spurge, has been a motivational speaker and contributor to
radio and TV stations including CNN, CNBC, and KCBS. She has
authored several books including Portraits of the American Dream,
MCI: Failure is not an Option, and Money Clips. Throughout her
career she has served on numerous advisory committees and boards of
directors for philanthropic organizations, including Prostate
Cancer Foundation, The Geffen Playhouse, WorkingNation, Focused
Ultrasound Foundation, and Women in America.
“We are thrilled to welcome esteemed finance, investment, and
business leader, Lorraine Spurge, to our Advisory Board,” said Ken
Londoner, Chairman, CEO and Founder of BioSig. “Her knowledge
and expertise in business development, corporate finance,
institutional investment, and organizational leadership is second
to none. Credited with advising and helping to build well-known
companies, Lorraine stands out as one of the leading advocates for
access to capital for small and middle market companies. As a
Drexel alum, we believe Lorraine’s network will be of great benefit
to BioSig as we seek to expand our shareholder base and advance our
growth initiatives.”
Ms. Spurge commented, “I am at a point in my life that I want to
support smart people, with the highest integrity, who are
passionate about advancing initiatives that improve and save lives.
Working with Michael Milken since 1981 has been the
greatest privilege, and, over the years, he has taught me to
help others to achieve their version of the American
Dream.
“At BioSig, Ken has assembled a professional team, and has
established the right motivational architecture for success. I am
pleased to join the Advisory Board with enthusiasm and a desire to
help save lives.”
About BioSig TechnologiesBioSig Technologies is
an advanced digital signal processing technology company bringing
never-before-seen insights to the treatment of cardiovascular
arrhythmias. Through collaboration with physicians, experts, and
healthcare leaders across the field of electrophysiology (EP),
BioSig is committed to addressing healthcare’s biggest priorities —
saving time, saving costs, and saving lives.
The Company’s first product, the PURE EP™ System, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform insight-based,
highly targeted cardiac ablation procedures with increased
procedural efficiency and efficacy.
The PURE EP™ System is currently in a national commercial launch
and an integral part of well-respected healthcare systems, such as
Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic,
and Kansas City Heart Rhythm Institute. In a blinded clinical
study recently published in the Journal of Cardiovascular
Electrophysiology, electrophysiologists rated PURE EP™ as
equivalent or superior to conventional systems for 93.6% of signal
samples, with 75.2% earning a superior rating.
The global EP market is projected to reach $16B in 2028 with an
11.2% growth rate.1
Forward-looking Statements This press release
contains "forward-looking statements." Such statements may be
preceded by the words "intends," “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
1 Global Market Insights Inc. March 08, 2022.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024